Linagliptina Sandoz

Linagliptin, the active ingredient in Linagliptina Sandoz, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, often as part of a comprehensive diabetes management plan that includes diet and exercise.

GNH USA supplies Linagliptina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and consistent product quality.

Linagliptina Sandoz is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers blood glucose when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin. - Type 2 diabetes mellitus (adjunct to diet and exercise): helps achieve target HbA1c as part of lifestyle modification.

Common side effects are generally mild and may resolve without intervention.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: transient sensation of light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare skin disorder with blistering lesions.

Linagliptina Sandoz should be used with careful clinical assessment and monitoring. - Renal impairment: monitor renal function regularly. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Pregnancy: risk unknown; avoid unless clearly needed. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture.

Linagliptina Sandoz may interact with several drug classes; assessment of the interaction risk is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Combination with insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin effectiveness. - Diuretics: may affect glucose control. - ACE inhibitors: monitor renal function and potassium levels. - NSAIDs: watch for potential renal effects. - Anticoagulants: observe for any changes in bleeding risk.